Skip to main content
Presentation
Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.
2018 Gastrointestinal Cancers Symposium (2018)
  • Kenneth H. Yu, Cornell University
  • Simon Mantha, Lahey Hospital & Medical Center
  • Catherine Tjan, Memorial Sloan Kettering Cancer Center
  • Erica S. Kaufmann
  • Robin Brenner, Memorial Sloan Kettering Cancer Center
  • Maeve Aine Lowery, Memorial Sloan Kettering Cancer Center
  • Geoffrey Yuyat Ku, Memorial Sloan Kettering Cancer Center
  • Nitya Prabhakar Raj, Memorial Sloan Kettering Cancer Center
  • Marina Shcherba, Albert Einstein College of Medicine
  • Zoe Goldberg
  • Jia Li, Memorial Sloan Kettering Cancer Center
  • Alice Zervoudakis, Memorial Sloan Kettering Cancer Center
  • Audrey M. Hamilton, Memorial Sloan Kettering Cancer Center
  • Elizabeth Won, Memorial Sloan Kettering Cancer Center
  • Antonio Ucar
  • Richard K. G., Do, New York University
  • Eileen Mary O'Reilly, Cornell University
Publication Date
January, 2018
Location
San Francisco, CA
Citation Information
Kenneth H. Yu, Simon Mantha, Catherine Tjan, Erica S. Kaufmann, et al.. "Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis." 2018 Gastrointestinal Cancers Symposium (2018)
Available at: http://works.bepress.com/antonio-ucar/8/